Who are Dual Anti Platelet Therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dabigatran + clopidogrel, Edoxaban plus Single Antiplatelet Agent, Dabigatran + Ticagrelor, Rosuvastatin plus clopidogrel, Dual antiplatelet agent duration, OAC + clopicogrel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dual-anti-platelet-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Dual Anti Platelet Therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dual Anti Platelet Therapy (Dual Anti Platelet Therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent combination. Area: Cardiovascular.

phase 3 Antiplatelet agent combination Thromboxane A2 pathway and P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Dual Anti Platelet Therapy (Dual Anti Platelet Therapy) — Biosensors Europe SA. Dual antiplatelet therapy combines two antiplatelet agents to inhibit platelet aggregation through different mechanisms, reducing thrombotic events.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dual Anti Platelet Therapy TARGET	Dual Anti Platelet Therapy	Biosensors Europe SA	phase 3	Antiplatelet agent combination	Thromboxane A2 pathway and P2Y12 receptor
Dabigatran + clopidogrel	Dabigatran + clopidogrel	Zuyderland Medisch Centrum	marketed	Anticoagulant + antiplatelet agent combination	Thrombin (Factor IIa) and P2Y12 receptor
Edoxaban plus Single Antiplatelet Agent	Edoxaban plus Single Antiplatelet Agent	Gi-Byoung Nam	marketed	Factor Xa inhibitor + antiplatelet agent combination	Factor Xa (edoxaban component); P2Y12 or COX-1 (antiplatelet component, depending on agent)
Dabigatran + Ticagrelor	Dabigatran + Ticagrelor	Zuyderland Medisch Centrum	marketed	Anticoagulant + antiplatelet agent combination	Thrombin (Factor IIa) and P2Y12 receptor
Rosuvastatin plus clopidogrel	Rosuvastatin plus clopidogrel	Federal University of São Paulo	marketed	Statin plus antiplatelet agent combination	HMG-CoA reductase; P2Y12 receptor
Dual antiplatelet agent duration	Dual antiplatelet agent duration	Seoul National University Hospital	marketed	Antiplatelet agent combination	Cyclooxygenase (COX) and P2Y12 receptor
OAC + clopicogrel	OAC + clopicogrel	St. Antonius Hospital	marketed	Anticoagulant + antiplatelet agent combination	Coagulation cascade (OAC) and P2Y12 receptor (clopidogrel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent combination class)

Beijing Tiantan Hospital · 1 drug in this class
Biosensors Europe SA · 1 drug in this class
Inova Health Care Services · 1 drug in this class
Kyunghee University Medical Center · 1 drug in this class
Seoul National University Hospital · 1 drug in this class
The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
University Hospital, Bordeaux · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dual Anti Platelet Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/dual-anti-platelet-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab